The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer...
Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with schizophrenia, ha...
Many of the patients who respond better to clozapine (CLZ) than to typical antipsychotics still have...
Predictors of long-term (13 year) outcome of schizophrenia are reported for a representative cohort ...
Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with schizophrenia, ha...
Our aim was to, firstly, identify characteristics at first-episode of psychosis that are associated ...
In recent years, machine learning (ML) has been a promising approach in the research of treatment ou...
Introduction Our aim was to, firstly, identify characteristics at first-episode of psychosis that ar...
[[abstract]]Objective: Researchers, by studying first-generation antipsychotics, have established an...
Background: A proportion of people with treatment-resistant schizophrenia fail to show improvement ...
The outcome of first-episode psychosis (FEP) is highly variable, ranging from early sustained recove...
Abstract Background: As the burden of treatment-resistant schizophrenia (TRS) on patients and socie...
Altres ajuts: the Finnish Cultural Foundation (Grant number 2DC49079); Jalmari and Rauha Ahokas' Fou...
Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with schizophrenia, ha...
Many of the patients who respond better to clozapine (CLZ) than to typical antipsychotics still have...
Predictors of long-term (13 year) outcome of schizophrenia are reported for a representative cohort ...
Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with schizophrenia, ha...
Our aim was to, firstly, identify characteristics at first-episode of psychosis that are associated ...
In recent years, machine learning (ML) has been a promising approach in the research of treatment ou...
Introduction Our aim was to, firstly, identify characteristics at first-episode of psychosis that ar...
[[abstract]]Objective: Researchers, by studying first-generation antipsychotics, have established an...
Background: A proportion of people with treatment-resistant schizophrenia fail to show improvement ...
The outcome of first-episode psychosis (FEP) is highly variable, ranging from early sustained recove...
Abstract Background: As the burden of treatment-resistant schizophrenia (TRS) on patients and socie...
Altres ajuts: the Finnish Cultural Foundation (Grant number 2DC49079); Jalmari and Rauha Ahokas' Fou...
Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with schizophrenia, ha...
Many of the patients who respond better to clozapine (CLZ) than to typical antipsychotics still have...
Predictors of long-term (13 year) outcome of schizophrenia are reported for a representative cohort ...